The modification of conventional liposomes for targeted antimicrobial delivery to treat infectious diseases
Abstract Some of the most crucial turning points in the treatment strategies for some major infectious diseases including AIDS, malaria, and TB, have been reached with the introduction of antimicrobials and vaccines. Drug resistance and poor effectiveness are key limitations that need to be overcome...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-01-01
|
| Series: | Discover Nano |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s11671-024-04170-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571377553506304 |
|---|---|
| author | Nnamdi Ikemefuna Okafor Omobolanle Ayoyinka Omoteso Yahya E. Choonara |
| author_facet | Nnamdi Ikemefuna Okafor Omobolanle Ayoyinka Omoteso Yahya E. Choonara |
| author_sort | Nnamdi Ikemefuna Okafor |
| collection | DOAJ |
| description | Abstract Some of the most crucial turning points in the treatment strategies for some major infectious diseases including AIDS, malaria, and TB, have been reached with the introduction of antimicrobials and vaccines. Drug resistance and poor effectiveness are key limitations that need to be overcome. Conventional liposomes have been explored as a delivery system for infectious diseases bioactives to treat infectious diseases to provide an efficient approach to maximize the therapeutic outcomes, drug stability, targetability, to reduce the side-effects of antimicrobials, and enhance vaccine performance where necessary. However, as the pathological understanding of infectious diseases become more known, the need for more advanced liposomal technologies was born to continue having a profound effect on targeted chemotherapy for infectious diseases. This review therefore provides a concise incursion into the most recent and vogue liposomal formulations used to treat infectious diseases. An appraisal of immunological, stimuli-responsive, biomimetic and functionalized liposomes and other novel modifications to conventional liposomes is assimilated in sync with mutations of resistant pathogens. |
| format | Article |
| id | doaj-art-641fa26b49e34ceabe3cdf5fa31b4f51 |
| institution | Kabale University |
| issn | 2731-9229 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Nano |
| spelling | doaj-art-641fa26b49e34ceabe3cdf5fa31b4f512025-02-02T12:37:52ZengSpringerDiscover Nano2731-92292025-01-0120112910.1186/s11671-024-04170-xThe modification of conventional liposomes for targeted antimicrobial delivery to treat infectious diseasesNnamdi Ikemefuna Okafor0Omobolanle Ayoyinka Omoteso1Yahya E. Choonara2Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of WitwatersrandDepartment of Pharmaceutics and Industrial Pharmacy, University of IbadanWits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of WitwatersrandAbstract Some of the most crucial turning points in the treatment strategies for some major infectious diseases including AIDS, malaria, and TB, have been reached with the introduction of antimicrobials and vaccines. Drug resistance and poor effectiveness are key limitations that need to be overcome. Conventional liposomes have been explored as a delivery system for infectious diseases bioactives to treat infectious diseases to provide an efficient approach to maximize the therapeutic outcomes, drug stability, targetability, to reduce the side-effects of antimicrobials, and enhance vaccine performance where necessary. However, as the pathological understanding of infectious diseases become more known, the need for more advanced liposomal technologies was born to continue having a profound effect on targeted chemotherapy for infectious diseases. This review therefore provides a concise incursion into the most recent and vogue liposomal formulations used to treat infectious diseases. An appraisal of immunological, stimuli-responsive, biomimetic and functionalized liposomes and other novel modifications to conventional liposomes is assimilated in sync with mutations of resistant pathogens.https://doi.org/10.1186/s11671-024-04170-xLiposomesDelivery systemAntimicrobialsInfectious diseasesEncapsulationTargeted delivery |
| spellingShingle | Nnamdi Ikemefuna Okafor Omobolanle Ayoyinka Omoteso Yahya E. Choonara The modification of conventional liposomes for targeted antimicrobial delivery to treat infectious diseases Discover Nano Liposomes Delivery system Antimicrobials Infectious diseases Encapsulation Targeted delivery |
| title | The modification of conventional liposomes for targeted antimicrobial delivery to treat infectious diseases |
| title_full | The modification of conventional liposomes for targeted antimicrobial delivery to treat infectious diseases |
| title_fullStr | The modification of conventional liposomes for targeted antimicrobial delivery to treat infectious diseases |
| title_full_unstemmed | The modification of conventional liposomes for targeted antimicrobial delivery to treat infectious diseases |
| title_short | The modification of conventional liposomes for targeted antimicrobial delivery to treat infectious diseases |
| title_sort | modification of conventional liposomes for targeted antimicrobial delivery to treat infectious diseases |
| topic | Liposomes Delivery system Antimicrobials Infectious diseases Encapsulation Targeted delivery |
| url | https://doi.org/10.1186/s11671-024-04170-x |
| work_keys_str_mv | AT nnamdiikemefunaokafor themodificationofconventionalliposomesfortargetedantimicrobialdeliverytotreatinfectiousdiseases AT omobolanleayoyinkaomoteso themodificationofconventionalliposomesfortargetedantimicrobialdeliverytotreatinfectiousdiseases AT yahyaechoonara themodificationofconventionalliposomesfortargetedantimicrobialdeliverytotreatinfectiousdiseases AT nnamdiikemefunaokafor modificationofconventionalliposomesfortargetedantimicrobialdeliverytotreatinfectiousdiseases AT omobolanleayoyinkaomoteso modificationofconventionalliposomesfortargetedantimicrobialdeliverytotreatinfectiousdiseases AT yahyaechoonara modificationofconventionalliposomesfortargetedantimicrobialdeliverytotreatinfectiousdiseases |